**Supplementary Table S1.** Correlation between different treatment strategies and clinicopathological characteristics in advanced NSCLC patients

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| *n* (%) | |  | Anlotinib | Immunotherapy | A+P combination therapy | c2 | *P* |
| Age (years) | |  |  |  |  | 0.743 | 0.691 |
|  | < 60 | 73 (51.4%) | 29 | 17 | 27 |  |  |
|  | ≥60 | 69 (48.6%) | 26 | 13 | 30 |  |  |
| Gender | |  |  |  |  | 2.112 | 0.348 |
|  | Male | 106 (74.6%) | 38 | 25 | 43 |  |  |
|  | Female | 36 (25.4%) | 17 | 5 | 14 |  |  |
| Smoking history | |  |  |  |  | 2.380 | 0.304 |
|  | No | 44 (31.0%) | 21 | 7 | 16 |  |  |
|  | Yes | 98 (69.0%) | 34 | 23 | 41 |  |  |
| Surgery treatment | |  |  |  |  | 0.906 | 0.636 |
|  | No | 120 (84.5%) | 46 | 27 | 47 |  |  |
|  | Yes | 22 (15.5%) | 9 | 3 | 10 |  |  |
| No. of prior systemic regimens | |  |  |  |  | 6.606 | 0.158 |
|  | ≤2 | 46 (32.4%) | 15 | 8 | 23 |  |  |
|  | 3 | 68 (47.9%) | 30 | 18 | 20 |  |  |
|  | >3 | 28 (19.7%) | 10 | 4 | 14 |  |  |
| ECOG performance status | |  |  |  |  | 0.595 | 0.743 |
|  | 0-1 | 124 (87.3%) | 49 | 25 | 50 |  |  |
|  | 2 | 18 (12.7%) | 6 | 5 | 7 |  |  |
| Histological subtype | |  |  |  |  | 4.998 | 0.082 |
|  | Squamous cell carcinoma | 52 (36.6%) | 14 | 14 | 24 |  |  |
|  | Adenocarcinoma | 90 (63.4%) | 41 | 16 | 33 |  |  |
| TNM classification | |  |  |  |  | 0.757 | 0.685 |
|  | III | 14 (9.9%) | 5 | 2 | 7 |  |  |
|  | IV | 128 (90.1%) | 50 | 28 | 50 |  |  |
| Tumor invasion | |  |  |  |  | 8.709 | 0.191 |
|  | T1 | 2 (1.4%) | 2 | 0 | 0 |  |  |
|  | T2 | 7 (4.9%) | 5 | 0 | 2 |  |  |
|  | T3 | 22 (15.5%) | 8 | 3 | 11 |  |  |
|  | T4 | 111 (78.2%) | 40 | 27 | 44 |  |  |
| Lymph node metastasis | |  |  |  |  | 3.157 | 0.789 |
|  | N0 | 1 (0.7%) | 0 | 0 | 1 |  |  |
|  | N1 | 3 (2.1%) | 2 | 1 | 0 |  |  |
|  | N2 | 18 (12.7%) | 7 | 3 | 8 |  |  |
|  | N3 | 120 (84.5%) | 46 | 27 | 47 |  |  |
| Distant metastasis | |  |  |  |  | 0.757 | 0.685 |
|  | M0 | 14 (9.9%) | 5 | 2 | 7 |  |  |
|  | M1 | 128 (90.1%) | 50 | 28 | 50 |  |  |
| Metastatic sites | |  |  |  |  | 2.196 | 0.334 |
|  | <3 | 70 (49.3%) | 26 | 12 | 32 |  |  |
|  | ≥3 | 72 (50.7%) | 29 | 18 | 25 |  |  |
| Brain metastasis | |  |  |  |  | 6.118 | 0.047\* |
|  | No | 86 (60.6%) | 27 | 18 | 41 |  |  |
|  | Yes | 56 (39.4%) | 28 | 12 | 16 |  |  |
| Liver metastases | |  |  |  |  | 4.466 | 0.107 |
|  | No | 94 (66.2%) | 39 | 15 | 40 |  |  |
|  | Yes | 48 (33.8%) | 16 | 15 | 17 |  |  |
| Bone metastases | |  |  |  |  | 4.422 | 0.110 |
|  | No | 95 (66.9%) | 36 | 16 | 47 |  |  |
|  | Yes | 47 (33.1%) | 19 | 14 | 14 |  |  |
| PD-L1 TPS | |  |  |  |  | 6.521 | 0.367 |
|  | <1% | 11 (7.7%) | 2 | 1 | 8 |  |  |
|  | 1-49% | 25 (17.6%) | 12 | 6 | 7 |  |  |
|  | ≥50% | 22 (15.5%) | 8 | 5 | 9 |  |  |
|  | Unknown | 84 (59.2%) | 33 | 18 | 33 |  |  |
| EGFR mutation status | |  |  |  |  | 8.516 | 0.074 |
|  | Wild type (-) | 61 (43.0%) | 24 | 16 | 21 |  |  |
|  | Mutant (+) | 26 (18.3%) | 15 | 2 | 9 |  |  |
|  | Unknown | 55 (38.7%) | 16 | 12 | 27 |  |  |
| EGFR mutation subtype | |  |  |  |  | 2.981 | 0.811 |
|  | 19del | 11 (42.3%) | 7 | 0 | 4 |  |  |
|  | 21L858R | 12 (46.2%) | 7 | 1 | 4 |  |  |
|  | T90M | 2 (7.7%) | 1 | 0 | 1 |  |  |
|  | Others | 1 (3.8%) | 0 | 0 | 1 |  |  |
| Previous thoracic radiation therapy | |  |  |  |  | 1.423 | 0.491 |
|  | No | 104 (73.2%) | 41 | 24 | 39 |  |  |
|  | Yes | 38 (26.8%) | 14 | 6 | 18 |  |  |
| Previous antivascular drug therapy | |  |  |  |  | 1.398 | 0.497 |
|  | No | 112 (78.9%) | 42 | 26 | 44 |  |  |
|  | Yes | 30 (21.1%) | 13 | 4 | 13 |  |  |
| \**P*< 0.05 | |  |  |  |  |  |  |